Show simple item record

dc.contributor.authorSossen, B
dc.contributor.authorBroger, T
dc.contributor.authorKerkhoff, AD
dc.contributor.authorSchutz, C
dc.contributor.authorTrollip, A
dc.contributor.authorMoreau, E
dc.contributor.authorSchumacher, SG
dc.contributor.authorBurton, R
dc.contributor.authorWard, A
dc.contributor.authorWilkinson, RJ
dc.contributor.authorBarr, DA
dc.contributor.authorNicol, MP
dc.contributor.authorDenkinger, CM
dc.contributor.authorMeintjes, G
dc.date.accessioned2020-01-17T10:02:44Z
dc.date.available2020-01-17T10:02:44Z
dc.date.issued2020-01-09
dc.date.submitted2020-01-15
dc.identifier.issn1537-6591
dc.identifier.pmid31917832
dc.identifier.doi10.1093/cid/ciaa024
dc.identifier.urihttp://hdl.handle.net/10144/619578
dc.description.abstractReducing diagnostic delay is key towards decreasing tuberculosis-associated deaths in people living with HIV. In tuberculosis patients with retrospective urine testing, the point-of-care Fujifilm SILVAMP TB LAM (FujiLAM) could have rapidly diagnosed tuberculosis in up to 89% who died. In FujiLAM negative patients, the probability of 12-week survival was 86-97%.en_US
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.rightsWith thanks to Oxford University Press.en_US
dc.title'SILVAMP TB LAM' rapid urine tuberculosis test predicts mortality in hospitalized HIV patients in South Africa.en_US
dc.identifier.journalClinical Infectious Diseasesen_US
dc.source.journaltitleClinical infectious diseases : an official publication of the Infectious Diseases Society of America
refterms.dateFOA2020-01-17T10:02:44Z


Files in this item

Thumbnail
Name:
Sossen et al 2020 ‘SILVAMP TB ...
Size:
636.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record